Make Better Decisions
helps generic and branded companies alike find and evaluate drug market entry opportunities.Billions of dollars can change hands when key drug patents expire and generics launch. Brands can experience precipitous revenue erosion as generic drugs rapidly gain market share. All the while patients, physicians, payers, pharmacists, and other healthcare stakeholders must race to keep up.
answers the following questions to help you adapt:
When will key drug patents expire?
How can I write stronger patents?
How can I defeat drug patents?
How can I find, evaluate, and plan for generic market entry opportunities?
How can I find proprietary out-of-court settlements and deal terms?
Comprehensive and actionable coverage of commercial, legal, and regulatory factors builds a solid foundation for strategic thinking. Diverse case studies build on this groundwork by analyzing and explaining real-work examples to form the underpinning for your tactical plans.Author Yali Friedman, Ph.D. has more than 20 years experience providing business intelligence to life science companies. He was recently named one of the 100 most influential people in biotechnology by
Scientific American
. He is also author of the MBA-level textbook
Building Biotechnology
and publisher of the
Journal of Commercial Biotechnology
.